We recently published a list of Jim Cramer’s Thoughts on These 10 Stocks. In this article, we are going to take a look at ...

Morgan Stanley analyst Terence Flynn reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of $63.00. The company’s shares opened toda ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of $75.00. The company’s share ...

Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

Biohaven (NYSE:BHVN) stock gains on tumor-shrinking results for the company's cancer drug BHV-1510 with Regeneron's (REGN) ...

Fintel reports that on May 19, 2025, RBC Capital downgraded their outlook for Biohaven (NYSE:BHVN) from Outperform to Sector ...

Biohaven (BHVN) stock slides as the FDA delays review of its lead drug troriluzole for a neurological condition called spinocerebellar ataxia. Read more here.

Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

BHVN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

In trading on Thursday, shares of Biohaven Ltd (Symbol: BHVN) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $28.47 per share. By comparison ...

Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company’s potential treatment for a rare disease. The FDA’s Decision on BHVN’s Drug Candidate The FDA agreed to review BHVN ...